VALBIOTIS SA: Valbiotis Presents the Full Results of the Phase II/III REVERSE-IT Study: Impressive Efficacy of TOTUM•63 Against Prediabetes and the Early Stages of Type 2 Diabetes, a First for a Non-drug Active Substance
The REVERSE-IT study has met its primary endpoint: TOTUM•63 reduced fasting blood glucose at 6 months versus placebo, on both...